What is Chardan Capital's Estimate for PVLA FY2025 Earnings?

Palvella Therapeutics (NASDAQ:PVLA - Free Report) - Investment analysts at Chardan Capital issued their FY2025 earnings per share estimates for Palvella Therapeutics in a research report issued to clients and investors on Wednesday, April 9th. Chardan Capital analyst G. Livshits forecasts that the company will post earnings per share of ($2.43) for the year. Chardan Capital has a "Buy" rating and a $50.00 price objective on the stock. The consensus estimate for Palvella Therapeutics' current full-year earnings is ($3.69) per share. Chardan Capital also issued estimates for Palvella Therapeutics' FY2026 earnings at ($3.06) EPS.

PVLA has been the subject of a number of other research reports. TD Cowen assumed coverage on Palvella Therapeutics in a research note on Wednesday, February 5th. They issued a "buy" rating and a $44.00 price objective for the company. Stifel Nicolaus began coverage on Palvella Therapeutics in a report on Wednesday, March 26th. They issued a "buy" rating and a $45.00 target price on the stock. Cantor Fitzgerald assumed coverage on shares of Palvella Therapeutics in a research note on Wednesday, December 18th. They issued an "overweight" rating on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $39.00 target price on shares of Palvella Therapeutics in a report on Wednesday, February 26th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $38.00 price objective on shares of Palvella Therapeutics in a report on Tuesday, April 1st. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $44.43.

Remove Ads

Palvella Therapeutics Stock Performance

Shares of Palvella Therapeutics stock traded down $0.51 during trading hours on Monday, hitting $23.93. The company had a trading volume of 47,774 shares, compared to its average volume of 66,517. Palvella Therapeutics has a twelve month low of $6.20 and a twelve month high of $29.27. The firm has a market cap of $263.68 million, a P/E ratio of -1.98 and a beta of 0.10. The company's 50-day moving average price is $22.76.

Insider Transactions at Palvella Therapeutics

In other news, Director George M. Jenkins purchased 2,500 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was bought at an average cost of $20.13 per share, for a total transaction of $50,325.00. Following the completion of the purchase, the director now directly owns 183,171 shares of the company's stock, valued at $3,687,232.23. The trade was a 1.38 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 6.39% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC acquired a new stake in Palvella Therapeutics in the fourth quarter valued at approximately $125,000. Toronto Dominion Bank purchased a new position in Palvella Therapeutics in the 4th quarter valued at about $159,000. Geode Capital Management LLC acquired a new stake in shares of Palvella Therapeutics during the fourth quarter valued at about $171,000. Cresset Asset Management LLC purchased a new position in Palvella Therapeutics in the fourth quarter valued at about $251,000. Finally, Renaissance Technologies LLC bought a new stake in shares of Palvella Therapeutics in the fourth quarter worth $256,000. 40.11% of the stock is owned by hedge funds and other institutional investors.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.